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Drug overdose accounted for 52 404 deaths in the United States in 2015,1 which are more 
deaths than for AIDS at its peak in 1995. Provisional data from the US Centers for Disease 
Control and Prevention (CDC) indicate drug overdose deaths increased again from 2015 to 
2016 by more than 20% (from 52 898 deaths in the year ending in January 2016 to 64 070 
deaths in the year ending in January 2017).2 Increases are greatest forover-doses related to 
the category including illicitly manufactured fentanyl (ie, synthetic opioids excluding 
methadone), which more than doubled, accounting for more than 20 000 overdose deaths in 
2016 vs less than 10 000 deaths in 2015. This difference is enough to account for nearly all 
the increase in drug overdose deaths from 2015 to 2016.2
Since 2010, overdose deaths involving predominantly illicit opioids (heroin, synthetic 
nonmethadone opioids, or both) have increased by more than 200% (Figure). Why have 
overdose deaths related to illicit opioids increased so substantially? Data from the National 
Survey on Drug Use and Health reveal moderate increases in people reporting past-year 
heroin use from 2010 to 2015 (Figure). Increasing numbers of individuals who use heroin 
are younger, might be less experienced, and might use heroin in riskier ways that are 
difficult to measure (eg, using it alone, using more heroin, using it more often, or combining 
drugs).
Although increased heroin use and risk taking likely contribute, available data suggest 
contamination of the heroin supply with illicitly manufactured fentanyl as the overwhelming 
driver of the recent increases in opioid-related overdose deaths. Illicitly manufactured 
fentanyl is usually added to or sold as heroin. For every individual using heroin during 
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recent years in the United States, it is likely that the risk of overdose death has increased 
considerably.
Fentanyl is approximately 50 times as potent as heroin. This provides strong economic 
incentives for drug dealers to mix fentanyl with heroin and other drugs because smaller 
volumes can provide equally powerful effects with lower costs and easier transport. Many 
people who use heroin are not seeking fentanyl and try to avoid it.3 It can be difficult to 
identify fentanyl, particularly in the white powder heroin typically sold in states east of the 
Mississippi River.4 The black tar and brown powder heroin typically sold in Western states 
might be limiting the penetration of fentanyl into this market for now. Among jurisdictions 
reporting provisional 2016 data, increases in drug overdose deaths since 2015 were much 
greater east of the Mississippi River.2
There are limited data about the effectiveness of interventions to prevent overdoses related to 
illicitly manufactured fentanyl. However, interventions that reduce opioid use disorder and 
opioid overdoses are likely to reduce overdoses related to illicitly manufactured fentanyl. 
Unnecessary exposure to prescription opioids must be reduced to prevent development of 
opioid use disorder in the first place. Despite recent progress, 3 times the amount of opioids 
were prescribed in 2015 compared with 1999 (Figure). Among people ultimately entering 
treatment for opioid use disorder, the proportion starting with prescription opioids rather 
than heroin has decreased in 1 study5 from more than 90% in 2005 to 67% in 2015. 
However, prescription opioid exposure remains a path to heroin use.
Clinicians need to identify and engage individual patients in offices, clinics, and emergency 
departments who are in need of and ready for effective opioid use disorder treatment, and 
offer or arrange medication-assisted treatment. The ability to treat opioid use disorder should 
become a routine part of medical care, with expectations that all practices have adequate 
capacity to provide effective treatment. Treatment should be available for patients with 
opioid use disorder and at risk for overdose, starting with those who survive a drug overdose.
Emergency department protocols could be developed to provide buprenorphine induction 
and short-duration buprenorphine prescriptions to bridge to longer-term treatment.6 Patient 
navigators could support linkage to treatment. Collaboration with law enforcement is 
necessary to link preventive services and effective treatment. For example, providing 
medication-assisted treatment in prisons increases the probability that incarcerated persons 
with opioid use disorder, who are at high risk of overdose after release, will engage with 
treatment after release.7 First responders and close associates of people who use drugs need 
adequate supplies of naloxone and training to reverse opioid overdose, so those who 
overdose can be kept alive and have a chance to start treatment.
Near real-time data are needed to drive rapid, coordinated community responses to increases 
in opioid overdoses. The CDC is working with 32 states and the District of Columbia to 
improve use of syndromic surveillance and emergency medical services data and identify 
increases in overdoses more quickly.
Patients and communities must be educated about the risks of opioid use. People with opioid 
use disorder and their families need to know about evidence-based treatment, so that 
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resources and lives are not squandered pursuing ineffective or harmful therapies. People who 
use drugs require education about the risks of fentanyl contamination in heroin and other 
drugs, including cocaine and counterfeit prescription opioids. In most areas of the United 
States (excluding some Western states for now), people who use heroin should assume the 
local supply is contaminated with fentanyl. The safest strategy is to avoid exposure to heroin 
and seek effective treatment. People who are unable to do this can reduce risk by avoiding 
use while alone, and making sure associates have and know how to use naloxone.
The current opioid crisis has evolved over the past 2 decades and is unlikely to be resolved 
soon. Opioid use and abuse has taken the lives of hundreds of thousands of people in the 
United States and is likely to adversely affect and end many more lives. Concerted, 
multifaceted action, including reducing exposure to illicitly manufactured fentanyl, will be 
necessary to reduce the catastrophic toll of opioid-related deaths.
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Figure. Opioid Use and Overdose and Fentanyl Drug Reports, 1999–2015
aSource: National Center for Health Statistics at the US Centers for Disease Control and 
Prevention. WONDER online database: prescription opioid overdose deaths include fatal 
overdoses related to natural and semisynthetic opioids or methadone. Illicit opioid-related 
overdose deaths are related to heroin or synthetic nonmethadone opioids, and some overdose 
deaths are related to prescribed fentanyl or other prescribed synthetic opioids.
bSource: Substance Abuse and Mental Health Services Administration. National Survey on 
Drug Use and Health. https://www.samhsa.gov/data/population-data-nsduh/reports?tab=38.
c Sources: Dashed line from 1999 to 2005 (Drug Enforcement Administration. Automation 
of Reports and Consolidated Orders System: sales to pharmacies, hospitals, and practitioners 
for codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, and 
oxycodone. Paulozzi LJ, et al. MMWR Morb Mortal Wkly Rep. 2011;60:1487–1492). Solid 
line from 2006 to 2015 (QuintilesIMS estimates of opioid prescriptions dispensed in the 
United States to 59 000 pharmacies, representing 88% of US prescriptions. Guy GP Jr, et al. 
MMWR Morb Mortal Wkly Rep. 2017;66:697–704).
dSource: Drug Enforcement Administration. Fentanyl, 2001–2015. https://
www.deadiversion.usdoj.gov/nflis/2017fentanyl.pdf. The number of fentanyl drug reports 
reflects the number of encounters by law enforcement that tested positive for fentanyl. 
Therefore, fentanyl drug reports provide an indication of the available supply of illicitly 
manufactured fentanyl.
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